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Abstract
Background: Familial partial lipodystrophy of the Dunnigan type (FPLD 2) is a rare autosomal dominant
disorder caused by the mutations of the lamin A/C gene leading to the defective adipogenesis, premature
death of adipocytes and lipotoxicity. FPLD 2 is characterized by a progressive loss of subcutaneous adipose
tissue in the limbs and trunk, and accumulation of body fat in the face and neck with accompanying
severe metabolic derangements including insulin resistance, glucose intolerance, diabetes, dyslipidemia,
steatohepatitis. Clinical presentation of FPLD 2 can often lead to misdiagnosis with metabolic syndrome,
type 2 diabetes or Cushing syndrome.
Case presentation: We report a case of a 14-year-old girl admitted to the Department of Paediatrics due
to chronic hypertransaminasemia. On physical examination the girl appeared to have athletic posture. She
demonstrated the absence of subcutaneous adipose tissue in the extremities, sparing the face, neck and
gluteal area, pseudo-hypertrophy of calves, prominent peripheral veins of limbs, massive acanthosis
nigricans around the neck, in axillary and inguinal regions and natural skin folds, hepatosplenomegaly.
Laboratory results revealed hypertransaminasemia, elevated γ-glutamyltranspeptydase, and dyslipidemia,
hyperinsulinaemia with insulin resistance, impaired glucose tolerance, and hyperuricemia. Diffuse
steatoheptitis in the liver biopsy was stated. Clinical suspicion of FPLD 2 was confirmed genetically. The
pathogenic mutation, R482W (p.Arg482Trp), responsible for the FPLD 2 phenotype was identified in one
allele of the LMNA gene.
Conclusions: Presented case highlights the importance of the holistic approach to a patient and the
need of accomplished collaboration between paediatricians and geneticists. FPLD 2 should be considered
in the differential diagnosis of diabetes, dyslipidemia, steatohepatitis, acanthosis nigricans and polycystic
ovary syndrome.
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Background
Lipodystrophy refers to a wide array of congenital or
acquired syndromes manifesting with the general or
partial absence of subcutaneous adipose tissue, which
are frequently associated with metabolic derangements
[1]. Familial partial lipodystrophy of the Dunnigan type
(FPLD 2; OMIM #151660) is a rare autosomal dominant
disorder defined by a progressive loss of body fat in the
limbs and trunk with an accompanying accumulation
of subcutaneous adipose tissue in the face and neck
leading to severe metabolic consequences i.e. insulin
resistance, glucose intolerance, diabetes, hyperlipid-
emia, steatohepatitis [1]. Patients with FPLD 2 may be
misdiagnosed with metabolic syndrome, type 2 diabetes or
Cushing syndrome [1].
FPLD 2 is caused by the mutations of the lamin A/C
gene (LMNA) located on chromosome 1q21-22 [1, 2].
The LMNA gene encodes A-type lamins - proteins,
which contribute in the maintenance of nuclear struc-
ture, transcriptional regulation and heterochromatin
organization [3]. The majority of LMNA mutations are
heterozygous, missense mutations of 482nd codon (with
variable aminoacid substitution; p.R482W/Q/L) lead-
ing to the defective adipogenesis, premature death of
adipocytes and lipotoxicity [4, 5].
We present a unique case of an adolescent girl who
remained under the comprehensive supervision of derma-
tologist due to acanthosis nigricans and gynaecologist due
to suspicion of polycystic ovary syndrome. She was admit-
ted to the Department of Paediatrics with chronic hyper-
transaminasemia at the age of 14 years old. The liver
biopsy showed features of steatohepatitis. However, it was
not the final diagnosis but just another piece of the puzzle.
Medical history, clinical phenotype and the results of
additional tests strongly suggested FPLD2, which was
confirmed by molecular testing. Although our patient
remained under the comprehensive supervision of paedia-
trician, dermatologist and gynaecologist, the final diagno-
sis was stated at the age of 14 years. It should be stressed,
that despite young age of our patient, the delay in FPLD2
diagnosis led to severe metabolic derangements and
decreased quality of life. We present that case to highlight
the importance of clinical acumen and holistic approach
to a patient based on thorough medical history and careful
physical examination. We would like to emphasise that
the recognition of steatohepatitis should alert one to the
possible diagnosis of rare metabolic disorder including
FPLD2. We believe that present case report will improve
the awareness of FPLD2 among paediatricians and result
in earlier diagnosis of that disorder.
Case presentation
A 14-year-old Caucasian girl was admitted to the
Department of Paediatrics, Medical University of Lublin,
Poland, for hypertransaminasemia of six months’ duration,
which was stated for the first time in laboratory tests
performed due to acanthosis nigricans by dermatologist.
The girl was born preterm at 36 weeks of gestation by
caesarean section after uncomplicated first pregnancy.
Her birth weight was 2,050 g. At the first minute after
birth the Apgar score was 9. The neonatal period was
complicated by prematurity problems i.e. pneumonia,
sepsis, anaemia and prolonged jaundice. Afterwards,
normal mental and physical development was observed.
Till puberty she had no relevant medical history. Since
menarche which occurred at the age of 11 years, she
noticed gradual loss of body fat and acanthosis nigricans
around her neck, in axillary and inguinal regions. She
subsequently developed an athletic appearance (Fig. 1).
She also suffered from oligomenorrhea. Changes in the
physical appearance did not disturb her, because her
Fig. 1 Patient with the Dunnigan-type familial partial lipodystrophy
Fig. 2 Selected features of the Dunnigan-type familial partial
lipodystrophy. a Pseudohypertrophia of calves, prominent peripheral
veins of lower limbs. b Massive acanthosis nigricans. c Acanthosis
nigricans, acne lesions on the trunk
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mother and grandmother presented similar silhouette.
However, both mother and grandmother of our patient
deny any medical conditions and they did not consent
on any further diagnostic evaluation.
On physical examination, the girl appeared to have ath-
letic posture. She demonstrated the absence of subcutane-
ous adipose tissue in the arms and legs, sparing the face,
neck and gluteal area, fat accumulation in the pubic and
vulva area, hypertrophy of skeletal muscles particularly of
calves, prominent peripheral veins of the limbs, hirsutism,
hypomastia. Massive acanthosis nigricans was seen around
the neck, in axillary and inguinal regions and in natural skin
folds. Acne lesions occurred on the face and upper trunk.
On both shins small subcutaneous lipomas were palpable.
The liver edge was palpable about 1.5 cm below the right
costal margin. Spleen was no palpable. She had elevated
blood pressure (155/80 mmHg). Selected features of FPLD
2 in our patient are presented in Figure 2.
Her weight was 60.3 kg (75-90th percentile), height
162 cm (50th percentile), body mass index 22.5 kg/m2
(75-90th percentile) and waist to hip ratio was 0.88. She
had disproportionately short limbs compared to the
trunk, with height to leg length ratio almost 2:1. Bi-
acromial distance (35.4 cm) was greater than bi-
trochanteric (26.7 cm), giving her impression of large
build. The sum of three skin folds was at 25th percentile.
The chest circumference was excessive (>97th per-
centile), with large chest width and depth (90-97th
percentile). In the bioelectrical impedance analysis
(BIA) total fat mass was 21 %.
Laboratory results revealed hypertransaminasemia, ele-
vated γ-glutamyltranspeptydase, hypercholesterolemia,
hypertriglyceridemia, hyperinsulinaemia, insulin resist-
ance, impaired glucose tolerance, decreased adiponectin,
increased creatine kinase MB and hyperuricemia. De-
tailed diagnostics was performed to determine the cause
of hypertransaminasemia. We excluded viral hepatitis
Table 1 Selected laboratory results of the patient
Parameter Result Reference range
Bilirubin [mg/dL] 1.09 <1,5
ALT [U/L] 222 <23
AST [U/L] 97 <25
GGT [U/L] 120 <23
Creatinin [mg/dL] 0.6 0.5 – 1.1
Urea [mg/dL] 29 19 – 49
Uric acid [mg/dL] 8.6 5.7
Oral glucose tolerance test
Fasting plasma glucose [mg/dL] 80 ≤126
30 min glucose [mg/dL] 119
2 h glucose [mg/dL] 154 <140
Insulin after glucose load
Fasting plasma insulin [mU/L] 77.1 3-25
30 min insulin [mU/L] 375.6 3-25




HbA1C [%] 4.6 % 4-6 %
Fructosamine [μmol/L] 265 100-285
C-peptide [ng/mL] 7.77 0.81-3.85
Lipids profile
Total cholesterol [mg/dL] 230 115 – 190
HDL [mg/dL] 43.7 >40
LDL [mg/dL] 132
Triglycerides [mg/dL] 271 <150
Adiponectin [μg/mL] 2.2 >10
Leptin [μg/L] 7.7 2.43-28
Anti-Hbe antibodies negative negative
HBs antigen negative negative
Anti-HCV antibodies negative negative
Anti-EBV antibodies negative negative
Anti-CMV antibodies negative negative
Anti-HIV antibodies negative negative
α-1-antitrypsin [g/L] 1.3 0.9-2.0
Ceruloplasmin [g/L] 0.2 0.16-0.45






Complement Component C3[mg/dL] 198.4 85-160
Complement Component C4[mg/dL] 25.3 12-36
Table 1 Selected laboratory results of the patient (Continued)
IgG [mg/dL] 1053 716-1711
Adrenocorticotropic hormone [pg/mL] 28.07 7.2-63.6
Cortisol [μg/dL] 6 am 20.4 4.3-22.4
Cortisol [μg/dL] 7 pm 2.2 <16.66
FSH [mIU/mL ] 5.24 1-7.4
LH [mIU/mL ] 7.34 0.5-15
Estradiol [pg/mL] 46.75 25-345
Progesterone [ng/mL] 0.56 0.55-12.3
Testosterone [ng/dL] 40.78 28-1110
SHBG [nmol/L] 17.55 26.1-100
17-OH-Progesterone [ng/mL] 2.33 1-4.5
DHEA-S [μg/dL] 204.9 33.9-280
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caused by hepatitis B virus, hepatitis C virus, cytomegalo-
virus, Ebstein – Barr virus and human immunodeficiency
virus, autoimmune hepatitis, α1-antitrypsin deficiency,
and Wilson’s disease. Table 1 presents selected laboratory
results of our patient.
In abdomen ultrasound examination we found enlarged
steatotic liver, splenomegaly and polycystic ovaries.
The percutaneus liver biopsy revealed chronic diffuse
steatohepatitis.
Although, elevated blood pressure was noted during
routine measurement, there were no abnormalities in
24-hour blood pressure monitoring, echocardiography
and electrocardiogram.
Radiological evaluation of the skeletal system showed
no specific findings. No abnormalities were found during
ophthalmological examination.
The clinical picture strongly suggested FPLD 2. We
excluded acquired causes of lipodystrophy (HIV infec-
tion, deficiency of C4 and C4 complement components).
Genetic testing was performed to confirm FPLD 2 diagno-
sis. In order to perform the first step of genetic analysis 5
LMNA gene exons were selected (ex. 6,7,8,9,10). This selec-
tion was based on current database and literature findings
showing that molecular defects of 3’ gene region are often re-
lated to the clinical outcome of FPLD 2. After prior amplifi-
cation (PCR reaction) of selected regions, the direct DNA
sequencing based on Sanger method was performed and the
pathogenic mutation R482W (HGVS nomenclature:
NM_170707.2: c.1444C>T; NP_733821.1: p.Arg482Trp)
was identified in one allele of the LMNA gene (heterozygous
form). R482W mutation has been registered in The Human
Gene Mutation Database as a disease causing LMNA variant.
Therefore, due to the disease autosomal dominant mode of
inheritance, obtained genetic analysis confirmed the clinical
diagnosis of FPLD 2 in our patient. Result of the DNA
Sanger sequencing analysis of the LMNA gene in our patient
is presented in Figure 3. Other members of our patient’s
family did not consent for any clinical and genetic testing.
The girl was referred to the Department of Paediatric
Metabolic Diseases, Children’s Health Institute in Warsaw
for further care.
Discussion
The estimated incidence of FPLD 2 is 1 case per 15
million persons [1]. However, the real prevalence may be
1 out of 200, 000 [6]. Discrepancies in morbidity data
probably result from under-diagnosis of FPLD2 because
of its heterogeneous phenotype mimicking metabolic
syndrome, type 2 diabetes or Cushing syndrome [1]. To
date, there have been described three cases of FPLD 2 in
Poland [7–9].
In patients with FPLD 2, progressive loss of adipose
tissue starts in puberty and concerns extremities and
trunk making the muscles and veins of limbs more
prominent. Significant sign of FPLD 2 is pseudohypertro-
phy of calves. Patients acquire athletic appearance [1, 10].
However, excessive accumulation of body fat in the face
and neck may give Cushingoid appearance. Adipose tissue
is also deposited in intra-abdominal region, and in
women in vulva region [1]. Our patient’s phenotype is
consistent with previous observations of FPLD 2
patients reported in the literature.
Skeletal abnormalities include short lower extremities
with the height-to-legs-length ratio more than 2, greater
bi-acromial than bi-trochanteric distance, broad hands
with spindle-shaped fingers, and posture anomalies [1].
Retraction of Achilles tendons, deficiency of the pelvic
and shoulder girdle, myalgia, muscular weakness or
cramps may be also seen [1, 11, 12]. Our patient did not
present these symptoms.
The most striking skin manifestation of FPLD 2 is
acanthosis nigricans localized around the neck, in axillae
and periumbilical area, which is a manifestation of insu-
lin resistance. Other skin signs include seborrhoea, acne,
leuko-melanoderma, subcutanues lipomas [1]. In our
patient acanthosis nigricans and massive acne were the
reason for medical consultation.
Metabolic derangements in FPLD 2 result from lipo-
toxicity of spared adipose tissue and include insulin
resistance, diabetes and dyslipidemia, steatohepatitis,
hyperandrogenism, and polycystic ovary syndrome [4].
In our patient, results of diagnostic tests revealed
hyperinsulinaemia with insulin resistance, impaired
Fig. 3 Result of DNA Sanger sequencing analysis of the LMNA gene: within ex. 8 the single nucleotide substitution C > T in one LMNA allele has
been identified which is related to occurrence of p.Arg482Trp mutation in described patient. Sequencing result has been analyzed with usage of
the Mutation Surveyor software
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glucose tolerance, steatohepatitis, hypertriglyceridemia
and hypercholesterolemia. She had also significantly
decreased adiponectin serum level. Serum leptin level
was within laboratory ranges. However, serum leptin
level in our patient was less than 10 μg/L, which is
69 % sensitive and 78 % specific for lipodystrophy [1].
In FPLD 2 cardiovascular complications are also pre-
sented i.e. cardiomyopathy, hypertension, early atheroscler-
osis and microangiopathy. Our patient had the incident of
elevated blood pressure. However, other cardiovascular
derangements may appear in the future [1, 12].
In women with FPLD 2 fertility and obstetrical
complications are more common than in general
population. Vantyghem et al. showed that in LMNA-
mutated women the prevalence of polycystic ovary
syndrome was 54 %, infertility 28 %, miscarriages
50 %, gestational diabetes 36 %, and eclampsia and
foetal death 14 % [13]. Our patient exhibited a clinical
phenotype of polycystic ovary syndrome.
The molecular background of lipodystrophy in our
patient is the LMNA gene defect: R482W (p.Arg482Trp)
mutation which has been described as a pathogenic vari-
ant responsible for FPLD 2. The first reported FPLD
mutation of the LMNA gene was change at codon 482
in exone 8, which predicted the replacement of arginine
by glutamine (Arg482Gln) [14]. Subsequently, Shackleton
et al. identified five different missense mutations in LMNA
gene i.e. Arg482Trp, Arg482Gln, Arg482Leu, Lys486Asn,
Lys486Asn in ten kindred and three individuals with
familial partial lipodystrophy [15].
More than ten different clinical syndromes have been
attributed to LMNA mutations like FPLD 2, congenital
muscular dystrophy, dilated cardiomyopathy type 1A [2]
The wide phenotypic heterogeneity of diseases resulting
from a mutation in a single gene may be explained by the
variable roles of the nuclear lamina [2]. It has been
observed that the majority of mutations in FPLD 2 affect
the C-terminal domain of the lamin A/C protein, whereas
alterations responsible for dilated cardiomyopathy and
other diseases are usually clustered in the rod domain of
the protein [16]. Mutations causing classical FLPD 2 usu-
ally affect “hot-spot” codon R482 which is probably
responsible for decreased charge of specific surface
on the C-terminal domain of lamin A/C. However,
even in patients with the same LMNA genotype the
clinical heterogeneity is significant [17].The CARE
checklist is available as Additional file 1.
Conclusions
The diagnosis of FPLD 2 is based on the typical signs
and symptoms, requiring thorough medical approach to
a patient and targeted genetic analysis. Presented case
shows the importance of precise and wide clinical
description of patient’s outcome which indicates the
optimal molecular diagnostic procedure, especially in
such cases as LMNA gene which different mutations are
responsible for multiple disorders. FPLD 2 should be
considered in the differential diagnosis of diabetes, dyslip-
idemia, steatohepatitis, acanthosis nigricans and polycystic
ovary syndrome.
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